|Category:||Clinical Stage Biotech Company|
|Time:||15:15 – 15:30|
|Speaker:||Jesus MARTIN-GARCIA, CEO|
GeNeuro develops novel treatments against autoimmune and neurodegenerative diseases.
Lead asset: temelimab, a monoclonal antibody targeting HERV-W ENV, a strong activator of innate immunity and pathogenic to several nervous system cells.
o Phase 2 completed with temelimab against neurodegeneration in MS
o Phase 2 initiated with temelimab against neuropsychiatric symptoms post-COVID
o Preclinical MAb against ALS developed in partnership with NINDS